TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tum...
Gespeichert in:
| Veröffentlicht in: | Leukemia Jg. 26; H. 2; S. 236 - 243 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
Nature Publishing Group UK
01.02.2012
Nature Publishing Group |
| Schlagworte: | |
| ISSN: | 0887-6924, 1476-5551, 1476-5551 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02. Comparison with reference inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.
In vivo
, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. |
|---|---|
| AbstractList | TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02. Comparison with reference inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. Leukemia (2012) 26, 236-243; doi:10.1038/leu.2011.218; published online 23 August 2011 Keywords: TG02; CDK; JAK2; FLT3; multi-kinase inhibitor; AML TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02. Comparison with reference inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02. Comparison with reference inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias.TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02. Comparison with reference inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02. Comparison with reference inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells. In vivo , TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. |
| Audience | Academic |
| Author | Goh, K C Jayaraman, R Ethirajulu, K Cheong, A Hart, S Loh, Y K Hu, C Wood, J M Dymock, B W Sun, E T William, A D Burrows, F Tan, Y C Ong, L C Novotny-Diermayr, V Ong, K H |
| Author_xml | – sequence: 1 givenname: K C surname: Goh fullname: Goh, K C email: keechuan_goh@sbio.com organization: SBIO Pte Ltd – sequence: 2 givenname: V surname: Novotny-Diermayr fullname: Novotny-Diermayr, V organization: SBIO Pte Ltd – sequence: 3 givenname: S surname: Hart fullname: Hart, S organization: SBIO Pte Ltd – sequence: 4 givenname: L C surname: Ong fullname: Ong, L C organization: SBIO Pte Ltd – sequence: 5 givenname: Y K surname: Loh fullname: Loh, Y K organization: SBIO Pte Ltd – sequence: 6 givenname: A surname: Cheong fullname: Cheong, A organization: SBIO Pte Ltd – sequence: 7 givenname: Y C surname: Tan fullname: Tan, Y C organization: SBIO Pte Ltd – sequence: 8 givenname: C surname: Hu fullname: Hu, C organization: SBIO Pte Ltd – sequence: 9 givenname: R surname: Jayaraman fullname: Jayaraman, R organization: SBIO Pte Ltd – sequence: 10 givenname: A D surname: William fullname: William, A D organization: SBIO Pte Ltd – sequence: 11 givenname: E T surname: Sun fullname: Sun, E T organization: SBIO Pte Ltd – sequence: 12 givenname: B W surname: Dymock fullname: Dymock, B W organization: SBIO Pte Ltd – sequence: 13 givenname: K H surname: Ong fullname: Ong, K H organization: Tan Tock Seng Hospital – sequence: 14 givenname: K surname: Ethirajulu fullname: Ethirajulu, K organization: SBIO Pte Ltd – sequence: 15 givenname: F surname: Burrows fullname: Burrows, F organization: Tragara Pharmaceuticals – sequence: 16 givenname: J M surname: Wood fullname: Wood, J M organization: SBIO Pte Ltd |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25698209$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21860433$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0s1v0zAUAHALDbFucOOMLBBwaYo_Esc5VoMNWCUu5Wy5ibN6c-3OdkD897zQTvvQJuSDJef3_F6e3xE68MEbhF5TMqOEy0_ODDNGKJ0xKp-hCS1rUVRVRQ_QhEhZF6Jh5SE6SumSkPGjeIEOgQpScj5BZnlG2BRr7MMv43CI2uHN4LItrqzXyWDr13Zlc4g49Pjk83ma4u_zc4a17_DpYsnxb5vXeBuy8RkOIRAKujIb2-JtDFsTszXpJXrea5fMq_1-jH6eflmefC0WP86-ncwXRVuVPBecV7LtqOSc1A0XutGM1Y1phOhY39VUVpURq5HoVV3KqhNlRZqeiVZropnmx-jj7l5IfT2YlNXGptY4p70JQ1KNkLTm0Jz_S0ZpySQVIN8-kJdhiB5-AxA8ANRQA3r3FGIjoDVp7qgL7Yyyvg856nZMrOZMElD1v9JmjyhY3dhVePzewvm9gA93AtZGu7xOwQ3ZBp_uwzf7KofVxnRqG-1Gxz_qZhwAvN8DnVrt-qh9a9Otq0QjGWnAsZ1rY0gpml61NusxH5RqnaJEjbOpYBTUOJtjBgiaPgi6ufcJXux4AuYvTLxt6aP-Lz_J7HM |
| CODEN | LEUKED |
| CitedBy_id | crossref_primary_10_1016_j_blre_2019_100634 crossref_primary_10_1042_BST20190338 crossref_primary_10_1016_j_jbior_2014_05_004 crossref_primary_10_3390_ph15070859 crossref_primary_10_1002_med_21354 crossref_primary_10_1080_14756366_2021_1890726 crossref_primary_10_4155_fmc_2022_0064 crossref_primary_10_1080_13543784_2019_1678583 crossref_primary_10_1080_15384101_2016_1138186 crossref_primary_10_3390_cancers13081795 crossref_primary_10_3390_cancers13102497 crossref_primary_10_1016_j_pharmthera_2017_02_008 crossref_primary_10_3390_cancers14051113 crossref_primary_10_1038_leu_2012_195 crossref_primary_10_3390_cancers13123039 crossref_primary_10_1038_s41408_021_00436_0 crossref_primary_10_3389_fonc_2019_01205 crossref_primary_10_1517_13543776_2015_1045414 crossref_primary_10_1002_bkcs_11280 crossref_primary_10_3390_ijms21093354 crossref_primary_10_4155_fmc_2016_0129 crossref_primary_10_3389_fgene_2016_00128 crossref_primary_10_1002_jcb_29916 crossref_primary_10_1186_s13046_018_0704_8 crossref_primary_10_3171_2021_5_PEDS20920 crossref_primary_10_1159_000542365 crossref_primary_10_3390_molecules190914366 crossref_primary_10_1038_s41392_023_01589_z crossref_primary_10_1016_j_canlet_2017_01_034 crossref_primary_10_1016_j_bmcl_2015_05_100 crossref_primary_10_3390_cancers11060837 crossref_primary_10_1016_j_blre_2015_12_002 crossref_primary_10_1016_j_bmcl_2019_126637 crossref_primary_10_3109_10428194_2013_783911 crossref_primary_10_1016_j_isci_2025_112283 crossref_primary_10_1053_j_seminoncol_2016_02_003 crossref_primary_10_1080_15384101_2015_1120915 crossref_primary_10_1186_s13045_021_01111_4 crossref_primary_10_3389_fonc_2021_678559 crossref_primary_10_3390_molecules25215199 crossref_primary_10_1182_blood_2013_05_505735 crossref_primary_10_1016_j_ejmech_2019_07_044 crossref_primary_10_3390_jcm9020593 crossref_primary_10_3390_ijms21030938 crossref_primary_10_1038_bcj_2011_43 crossref_primary_10_1111_bjh_12018 crossref_primary_10_1158_1078_0432_CCR_17_2032 crossref_primary_10_1158_1078_0432_CCR_20_4730 crossref_primary_10_2174_0109298673277543231205072556 crossref_primary_10_1182_bloodadvances_2017006122 crossref_primary_10_1158_1078_0432_CCR_12_2118 crossref_primary_10_1038_bcj_2012_14 crossref_primary_10_1517_13543784_2013_789859 crossref_primary_10_1080_13543784_2021_1850693 crossref_primary_10_3390_biomedicines9111591 crossref_primary_10_1586_17474086_2014_857596 crossref_primary_10_1186_2050_6511_14_32 crossref_primary_10_1016_j_ejmech_2022_114551 crossref_primary_10_1016_j_ejmech_2021_114056 crossref_primary_10_1002_ijc_32069 crossref_primary_10_1016_j_chembiol_2020_10_001 crossref_primary_10_1016_j_bcp_2024_116470 crossref_primary_10_1016_j_ejca_2023_113475 crossref_primary_10_1080_13543784_2016_1234603 crossref_primary_10_1016_j_neo_2019_05_001 crossref_primary_10_31083_j_fbs1603015 crossref_primary_10_3389_fonc_2024_1370565 crossref_primary_10_3390_molecules25040838 crossref_primary_10_3389_fonc_2020_626751 crossref_primary_10_1016_j_bmc_2024_117711 crossref_primary_10_1096_fj_202201217RR crossref_primary_10_1002_med_21856 |
| Cites_doi | 10.1517/14728214.11.1.153 10.1002/msj.20220 10.1038/nrd2907 10.1038/sj.leu.2401903 10.1200/JCO.2005.03.7689 10.1038/sj.leu.2401608 10.1038/nrc2210 10.1038/nrd2590 10.1158/0008-5472.CAN-06-1758 10.1242/jcs.00963 10.1111/j.0105-2896.2005.00220.x 10.1016/S0165-6147(02)02071-0 10.1111/j.1365-2141.2006.06291.x 10.1002/ijc.21485 10.1038/nrd2012 10.1002/ijc.25806 10.2174/156652405774641106 10.1016/j.ccr.2008.02.009 10.1186/1479-5876-4-41 10.1182/blood-2006-05-024018 10.1182/blood-2009-05-223727 10.1007/s00280-008-0921-5 10.1517/13543781003767418 10.1182/blood.V116.21.3082.3082 10.1007/s10637-011-9677-6 |
| ContentType | Journal Article |
| Copyright | Macmillan Publishers Limited 2012 2015 INIST-CNRS COPYRIGHT 2012 Nature Publishing Group Macmillan Publishers Limited 2012. Copyright Nature Publishing Group Feb 2012 |
| Copyright_xml | – notice: Macmillan Publishers Limited 2012 – notice: 2015 INIST-CNRS – notice: COPYRIGHT 2012 Nature Publishing Group – notice: Macmillan Publishers Limited 2012. – notice: Copyright Nature Publishing Group Feb 2012 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T5 7T7 7TM 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7N M7P NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1038/leu.2011.218 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Central Student MEDLINE - Academic Oncogenes and Growth Factors Abstracts ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1476-5551 |
| EndPage | 243 |
| ExternalDocumentID | 2581796521 A280717751 21860433 25698209 10_1038_leu_2011_218 |
| Genre | Journal Article |
| GeographicLocations | Singapore United States--US |
| GeographicLocations_xml | – name: Singapore – name: United States--US |
| GroupedDBID | --- -Q- .55 .XZ 0R~ 29L 2WC 36B 39C 3V. 4.4 406 53G 5GY 5RE 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AACDK AANZL AAQQT AASDW AASML AATNV AAWTL AAYZH AAZLF ABAKF ABAWZ ABDBF ABJNI ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACPRK ACRQY ACUHS ACZOJ ADBBV ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFFNX AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF ASPBG AVWKF AXYYD AZFZN B0M BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 E3Z EAD EAP EBC EBD EBLON EBS EBX EE. EIOEI EJD EMB EMK EMOBN EPL ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FIZPM FSGXE FYUFA HCIFZ HMCUK HVGLF HZ~ IAO IH2 IHR IHW INH INR ITC IWAJR JSO JZLTJ KQ8 LGEZI LOTEE M1P M7P N9A NADUK NAO NAPCQ NQJWS NXXTH O9- OK1 OVD P2P P6G PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT ROL SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UDS UKHRP WOW X7M Y6R ZGI ZXP ~8M AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB IQODW CGR CUY CVF ECM EIF NPM ACMFV 7QL 7T5 7T7 7TM 7TO 7U9 7XB 8FD 8FE 8FH 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c543t-3358cd183307936a9a2279e966d2fd71855e6b8cd1ab7485d64509f26caa0a2a3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 109 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000300419100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0887-6924 1476-5551 |
| IngestDate | Sun Nov 09 13:10:19 EST 2025 Thu Oct 02 14:05:29 EDT 2025 Mon Oct 06 17:04:36 EDT 2025 Mon Oct 06 17:23:13 EDT 2025 Sat Nov 29 12:56:52 EST 2025 Sat Nov 29 09:48:54 EST 2025 Thu May 22 21:23:03 EDT 2025 Mon Jul 21 06:03:47 EDT 2025 Mon Jul 21 09:10:45 EDT 2025 Tue Nov 18 21:56:01 EST 2025 Sat Nov 29 04:05:23 EST 2025 Fri Feb 21 02:38:01 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | multi-kinase inhibitor AML TG02 CDK JAK2 FLT3 Acute myelogenous leukemia Hematology Enzyme FLT3 gene JAK2 protein tyrosine kinase Transferases Malignant hemopathy trk receptor Cyclin dependent kinase inhibitor Kinase C-Onc gene Protein-tyrosine kinase Protooncogene Cancer |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c543t-3358cd183307936a9a2279e966d2fd71855e6b8cd1ab7485d64509f26caa0a2a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 21860433 |
| PQID | 2645717097 |
| PQPubID | 30521 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_968173551 proquest_miscellaneous_921142816 proquest_journals_920386457 proquest_journals_2645717097 gale_infotracmisc_A280717751 gale_infotracacademiconefile_A280717751 gale_healthsolutions_A280717751 pubmed_primary_21860433 pascalfrancis_primary_25698209 crossref_citationtrail_10_1038_leu_2011_218 crossref_primary_10_1038_leu_2011_218 springer_journals_10_1038_leu_2011_218 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-02-01 |
| PublicationDateYYYYMMDD | 2012-02-01 |
| PublicationDate_xml | – month: 02 year: 2012 text: 2012-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: Avenel, NJ – name: England |
| PublicationTitle | Leukemia |
| PublicationTitleAbbrev | Leukemia |
| PublicationTitleAlternate | Leukemia |
| PublicationYear | 2012 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Melzner, Weniger, Bucur, Bruderlein, Dorsch, Hasel (CR16) 2006; 118 Tyner, Bumm, Deininger, Wood, Aichberger, Loriaux (CR19) 2010; 115 Ikezoe, Yang, Nishioka, Kojima, Takeuchi, Koeffler (CR23) 2011; 128 Levine, Pardanani, Tefferi, Gilliland (CR24) 2007; 7 Baker, Reddy (CR1) 2010; 77 Conroy, Stockett, Walker, Arkin, Hoch, Fox (CR20) 2009; 64 Wernig, Kharas, Okabe, Moore, Leeman, Cullen (CR12) 2008; 13 Worns, Galle (CR3) 2010; 19 Bennett, Stroncek (CR8) 2006; 4 Hannah (CR21) 2005; 5 Shapiro (CR5) 2006; 24 Rawlings, Rosler, Harrison (CR7) 2004; 117 Jordan, Upchurch, Szilvassy, Guzman, Howard, Pettigrew (CR14) 2000; 14 CR2 Choudhary, Brandts, Schwable, Tickenbrock, Sargin, Ueker (CR15) 2007; 110 Lapenna, Giordano (CR11) 2009; 8 CR27 Atkins, Jones, Kirkpatrick (CR13) 2006; 5 Grandage, Everington, Linch, Khwaja (CR18) 2006; 135 CR22 Knockaert, Greengard, Meijer (CR4) 2002; 23 Tickenbrock, Muller-Tidow, Berdel, Serve (CR9) 2006; 11 Cai, Latham, Zhang, Shapiro (CR25) 2006; 66 Pesu, Candotti, Husa, Hofmann, Notarangelo, O’Shea (CR26) 2005; 203 Uozumi, Otsuka, Ohno, Moriyama, Suzuki, Shimotakahara (CR17) 2000; 14 Cai, Latham, Zhang, Shapiro (CR6) 2006; 66 Driggers, Hale, Lee, Terrett (CR10) 2008; 7 JW Tyner (BFleu2011218_CR19) 2010; 115 BFleu2011218_CR2 BFleu2011218_CR27 GI Shapiro (BFleu2011218_CR5) 2006; 24 JS Rawlings (BFleu2011218_CR7) 2004; 117 I Melzner (BFleu2011218_CR16) 2006; 118 C Choudhary (BFleu2011218_CR15) 2007; 110 EM Driggers (BFleu2011218_CR10) 2008; 7 S Lapenna (BFleu2011218_CR11) 2009; 8 A Conroy (BFleu2011218_CR20) 2009; 64 BFleu2011218_CR22 RL Levine (BFleu2011218_CR24) 2007; 7 D Cai (BFleu2011218_CR25) 2006; 66 M Pesu (BFleu2011218_CR26) 2005; 203 D Cai (BFleu2011218_CR6) 2006; 66 L Tickenbrock (BFleu2011218_CR9) 2006; 11 M Bennett (BFleu2011218_CR8) 2006; 4 K Uozumi (BFleu2011218_CR17) 2000; 14 T Ikezoe (BFleu2011218_CR23) 2011; 128 SJ Baker (BFleu2011218_CR1) 2010; 77 VL Grandage (BFleu2011218_CR18) 2006; 135 M Knockaert (BFleu2011218_CR4) 2002; 23 MA Worns (BFleu2011218_CR3) 2010; 19 G Wernig (BFleu2011218_CR12) 2008; 13 CT Jordan (BFleu2011218_CR14) 2000; 14 M Atkins (BFleu2011218_CR13) 2006; 5 AL Hannah (BFleu2011218_CR21) 2005; 5 |
| References_xml | – ident: CR22 – volume: 11 start-page: 153 year: 2006 end-page: 165 ident: CR9 article-title: Emerging Flt3 kinase inhibitors in the treatment of leukaemia publication-title: Expert Opin Emerg Drugs doi: 10.1517/14728214.11.1.153 – ident: CR2 – volume: 77 start-page: 573 year: 2010 end-page: 586 ident: CR1 article-title: Targeted inhibition of kinases in cancer therapy publication-title: Mt Sinai J Med doi: 10.1002/msj.20220 – volume: 8 start-page: 547 year: 2009 end-page: 566 ident: CR11 article-title: Cell cycle kinases as therapeutic targets for cancer publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2907 – volume: 14 start-page: 1777 year: 2000 end-page: 1784 ident: CR14 article-title: The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells publication-title: Leukemia doi: 10.1038/sj.leu.2401903 – volume: 24 start-page: 1770 year: 2006 end-page: 1783 ident: CR5 article-title: Cyclin-dependent kinase pathways as targets for cancer treatment publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.7689 – volume: 14 start-page: 142 year: 2000 end-page: 152 ident: CR17 article-title: Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles publication-title: Leukemia doi: 10.1038/sj.leu.2401608 – volume: 7 start-page: 673 year: 2007 end-page: 683 ident: CR24 article-title: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders publication-title: Nat Rev Cancer doi: 10.1038/nrc2210 – volume: 7 start-page: 608 year: 2008 end-page: 624 ident: CR10 article-title: The exploration of macrocycles for drug discovery—an underexploited structural class publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2590 – ident: CR27 – volume: 66 start-page: 9270 year: 2006 end-page: 9280 ident: CR6 article-title: Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-1758 – volume: 117 start-page: 1281 issue: Part 8 year: 2004 end-page: 1283 ident: CR7 article-title: The JAK/STAT signaling pathway publication-title: J Cell Sci doi: 10.1242/jcs.00963 – volume: 203 start-page: 127 year: 2005 end-page: 142 ident: CR26 article-title: Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2005.00220.x – volume: 23 start-page: 417 year: 2002 end-page: 425 ident: CR4 article-title: Pharmacological inhibitors of cyclin-dependent kinases publication-title: Trends Pharmacol Sci doi: 10.1016/S0165-6147(02)02071-0 – volume: 135 start-page: 303 year: 2006 end-page: 316 ident: CR18 article-title: Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2006.06291.x – volume: 118 start-page: 1941 year: 2006 end-page: 1944 ident: CR16 article-title: Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein publication-title: Int J Cancer doi: 10.1002/ijc.21485 – volume: 5 start-page: 279 year: 2006 end-page: 280 ident: CR13 article-title: Sunitinib maleate publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2012 – volume: 128 start-page: 2317 year: 2011 end-page: 2325 ident: CR23 article-title: Inhibition of STAT5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34(+)/CD38(−) cells and sensitizes them to anti-leukemia agents publication-title: Int J Cancer doi: 10.1002/ijc.25806 – volume: 5 start-page: 625 year: 2005 end-page: 642 ident: CR21 article-title: Kinases as drug discovery targets in hematologic malignancies publication-title: Curr Mol Med doi: 10.2174/156652405774641106 – volume: 13 start-page: 311 year: 2008 end-page: 320 ident: CR12 article-title: Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera publication-title: Cancer Cell doi: 10.1016/j.ccr.2008.02.009 – volume: 4 start-page: 41 year: 2006 ident: CR8 article-title: Recent advances in the bcr-abl negative chronic myeloproliferative diseases publication-title: J Transl Med doi: 10.1186/1479-5876-4-41 – volume: 110 start-page: 370 year: 2007 end-page: 374 ident: CR15 article-title: Activation mechanisms of STAT5 by oncogenic Flt3-ITD publication-title: Blood doi: 10.1182/blood-2006-05-024018 – volume: 115 start-page: 5232 year: 2010 end-page: 5240 ident: CR19 article-title: CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms publication-title: Blood doi: 10.1182/blood-2009-05-223727 – volume: 66 start-page: 9270 year: 2006 end-page: 9280 ident: CR25 article-title: Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-1758 – volume: 64 start-page: 723 year: 2009 end-page: 732 ident: CR20 article-title: SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-008-0921-5 – volume: 19 start-page: 615 year: 2010 end-page: 629 ident: CR3 article-title: Novel inhibitors in development for hepatocellular carcinoma publication-title: Expert Opin Investig Drugs doi: 10.1517/13543781003767418 – volume: 23 start-page: 417 year: 2002 ident: BFleu2011218_CR4 publication-title: Trends Pharmacol Sci doi: 10.1016/S0165-6147(02)02071-0 – volume: 14 start-page: 1777 year: 2000 ident: BFleu2011218_CR14 publication-title: Leukemia doi: 10.1038/sj.leu.2401903 – volume: 8 start-page: 547 year: 2009 ident: BFleu2011218_CR11 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2907 – ident: BFleu2011218_CR27 doi: 10.1182/blood.V116.21.3082.3082 – ident: BFleu2011218_CR22 – volume: 5 start-page: 279 year: 2006 ident: BFleu2011218_CR13 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2012 – volume: 19 start-page: 615 year: 2010 ident: BFleu2011218_CR3 publication-title: Expert Opin Investig Drugs doi: 10.1517/13543781003767418 – volume: 117 start-page: 1281 issue: Part 8 year: 2004 ident: BFleu2011218_CR7 publication-title: J Cell Sci doi: 10.1242/jcs.00963 – volume: 118 start-page: 1941 year: 2006 ident: BFleu2011218_CR16 publication-title: Int J Cancer doi: 10.1002/ijc.21485 – volume: 203 start-page: 127 year: 2005 ident: BFleu2011218_CR26 publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2005.00220.x – ident: BFleu2011218_CR2 doi: 10.1007/s10637-011-9677-6 – volume: 11 start-page: 153 year: 2006 ident: BFleu2011218_CR9 publication-title: Expert Opin Emerg Drugs doi: 10.1517/14728214.11.1.153 – volume: 7 start-page: 673 year: 2007 ident: BFleu2011218_CR24 publication-title: Nat Rev Cancer doi: 10.1038/nrc2210 – volume: 24 start-page: 1770 year: 2006 ident: BFleu2011218_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.7689 – volume: 66 start-page: 9270 year: 2006 ident: BFleu2011218_CR25 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-1758 – volume: 4 start-page: 41 year: 2006 ident: BFleu2011218_CR8 publication-title: J Transl Med doi: 10.1186/1479-5876-4-41 – volume: 128 start-page: 2317 year: 2011 ident: BFleu2011218_CR23 publication-title: Int J Cancer doi: 10.1002/ijc.25806 – volume: 66 start-page: 9270 year: 2006 ident: BFleu2011218_CR6 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-1758 – volume: 110 start-page: 370 year: 2007 ident: BFleu2011218_CR15 publication-title: Blood doi: 10.1182/blood-2006-05-024018 – volume: 13 start-page: 311 year: 2008 ident: BFleu2011218_CR12 publication-title: Cancer Cell doi: 10.1016/j.ccr.2008.02.009 – volume: 135 start-page: 303 year: 2006 ident: BFleu2011218_CR18 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2006.06291.x – volume: 5 start-page: 625 year: 2005 ident: BFleu2011218_CR21 publication-title: Curr Mol Med doi: 10.2174/156652405774641106 – volume: 115 start-page: 5232 year: 2010 ident: BFleu2011218_CR19 publication-title: Blood doi: 10.1182/blood-2009-05-223727 – volume: 14 start-page: 142 year: 2000 ident: BFleu2011218_CR17 publication-title: Leukemia doi: 10.1038/sj.leu.2401608 – volume: 7 start-page: 608 year: 2008 ident: BFleu2011218_CR10 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2590 – volume: 77 start-page: 573 year: 2010 ident: BFleu2011218_CR1 publication-title: Mt Sinai J Med doi: 10.1002/msj.20220 – volume: 64 start-page: 723 year: 2009 ident: BFleu2011218_CR20 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-008-0921-5 |
| SSID | ssj0014766 |
| Score | 2.398077 |
| Snippet | TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling... |
| SourceID | proquest gale pubmed pascalfrancis crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 236 |
| SubjectTerms | Acute myeloid leukemia Animal models Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Apoptosis Bioaccumulation Biological and medical sciences Cancer Cancer Research Care and treatment Cell cycle Cell Line, Transformed Cells (biology) Critical Care Medicine Cyclin-dependent kinase Cyclin-dependent kinases Cyclin-Dependent Kinases - antagonists & inhibitors Disease Models, Animal Dosage Dosage and administration Enzyme inhibitors Female fms-Like Tyrosine Kinase 3 - antagonists & inhibitors Hematologic and hematopoietic diseases Hematology Heterocyclic Compounds, 4 or More Rings - pharmacology Heterocyclic Compounds, 4 or More Rings - therapeutic use Humans Intensive Internal Medicine Janus kinase 2 Janus Kinase 2 - antagonists & inhibitors Kinases Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical prognosis Medical sciences Medicine Medicine & Public Health Mice Mice, Inbred BALB C Oncology original-article Patients Pharmacokinetics Polycythemia Polycythemia vera Progenitor cells Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Signaling Stem cells Tumor cell lines Tumors Xenografts Xenotransplantation |
| Title | TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties |
| URI | https://link.springer.com/article/10.1038/leu.2011.218 https://www.ncbi.nlm.nih.gov/pubmed/21860433 https://www.proquest.com/docview/2645717097 https://www.proquest.com/docview/920386457 https://www.proquest.com/docview/921142816 https://www.proquest.com/docview/968173551 |
| Volume | 26 |
| WOSCitedRecordID | wos000300419100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1476-5551 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0014766 issn: 0887-6924 databaseCode: M7P dateStart: 19970201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1476-5551 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0014766 issn: 0887-6924 databaseCode: 7X7 dateStart: 19970201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Source (ProQuest) customDbUrl: eissn: 1476-5551 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0014766 issn: 0887-6924 databaseCode: 7RV dateStart: 19970201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1476-5551 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0014766 issn: 0887-6924 databaseCode: BENPR dateStart: 19970201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Public Health Database customDbUrl: eissn: 1476-5551 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0014766 issn: 0887-6924 databaseCode: 8C1 dateStart: 19970201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1db9Mw0GIbQkiI74-wUfzAx8MWLXES23lCpawgNqpqKlPfIsdxRLUqCU27389d4qZUG3vhxQ_xRf64T_vOd4S800z5qYqlq1Oh3TCPUzc1nudmgHEjtGCqudO9OBOjkZxO47G9cKttWOVaJjaCOis13pEfg-KO4OjhxeJT9dvFqlHoXbUlNHbIHmZJCJrQvXHnRQhF66tERuJw0LCB714gj-dm1ebvZFju4y-VZAXzg0rVsEl5W93iJvPzmuu00UjDR_-7lsfkobVFab8lnifkjimekns_rLf9GTGTrx47oooW5ZWZU3zLT5sARPdyVoD2o7Pi1ywFkbCgZU4HX07rI_q9f8qoKjI6PJsEFG95aVWCXb6Ej_AjbMglhuPTCp0AC8zm-pz8HJ5MBt9cW5bB1VEYLN0giKTOQBQEmFyPq1hhFkID56aM5RnouigyPEUQlYpQRhms1otzxrVSnmIqeEF2i7IwrwgF64BnQnDN0jCEs1PK0zzzpInREmVcOuRwjZlE25zlWDpjnjS-80AmMO0E8ZgAHh3yvoOu2lwd_4B7i0hO2pemHYsnfcwM5AsR-Q752EAgk8N4Wtm3CjBrTJe1BXmwBQnMqbe6e1uE1M0LLM0YjK8Y_l-TSGKlR51s6MMh-9e7YwYrQhCH0K4XB8Z4ucKUKwTBN9LS57eAcOkLsDZhji9bit5MzpccE9s55MOaxDej37Sjr29fxT65D5CsDXY_ILvLxcq8IXf11XJWL3pkR5xfYDsVTSuhlQO_R_Y-n4zG572Gp_8AQHdJyQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3bbtMw9GgMxJAQ1wFhY_MDgwcWLXEudh4QqjbKRrsKoW7aW3AcR1SrktLLED_FN3JOLi3Vxt72wGt9XNvxufrcAF5rrtxERdLWidC2n0WJnRjHsVO8cSO04Kp80z3til5Pnp1FX1bgd5MLQ2GVDU8sGXVaaHoj30PBHaDp4UTiw-iHTV2jyLvatNCo0KJjfv1Ek23y_ugA73eH8_bH_v6hXXcVsHXge1Pb8wKpU8Rkj2rDhSpSVETPoNqf8ixFVh0EJkwIRCXCl0GKCztRxkOtlKO48vB_b8Ft5OMuhZCJr6dzr4UvKt8oEW6Ihk0daO94cm9oZlW9UE7tRf4SgbUguD9SE7yUrOqmcZW6e8lVW0rA9sP_7ds9gge1rs1aFXE8hhWTP4G7x3U0wVMw_U8O32WK5cWFGTKqVcDKAEv7fJCjdGeD_PsgQZY3ZkXG9g86k132udXhTOUpa3f7HqNXbDYq0O6Y4o84ES_gnNIN2IicHGOqVrsOJzdyyGewmhe5eQEMtZ8wFSLUPPF9tA2TMMlSR5qING0eSgveNZgQ67omO7UGGcZlbIAnY9x2THgTI95YsDOHHlW1SP4Bt01IFVeZtHMWFreo8pErROBa8LaEICaG62lV52Lgrqkc2BLk5hIkMh-9NLy1hLjzfaEmHaFyGeH8BiXjmjtO4gU-WrBxeTjieCICsYDNR2lhigfMTTEjEMoBl254DUgoXYHaNO7xeUVBi825MqTCfRa8aUhqsfpVX_Tl9afYhrXD_nE37h71OhtwD2fxKrB_E1an45l5BXf0xXQwGW-V_ILBt5smsj-lc5-_ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3LbtNAcFQKqpAQb4ppafdA4UCt2uvHrg8IRQmBkhD1EFBvZr1eq1EjO-RRxK_xdcz4kRC19NYD1-xsdtY7z915ALzSXLmJiqStE6FtP4sSOzGOY6d44kZowVV5p_utLwYDeXoanWzA7yYXhsIqG5lYCuq00HRHfoSKO0DXgwouZnVYxEmn-37yw6YOUvTS2rTTqEikZ379RPdt9u64g2d9wHn3w7D9ya47DNg68L257XmB1ClStUd14kIVKSqoZ9AFSHmWotgOAhMmBKIS4csgRSScKOOhVspRXHn4v7fgtvCQiilLvb0ML3F9Ub2TEhOH6OTUQfeOJ4_GZlHVDuXUauQvdVgrhXsTNcMDyqrOGleZvpeebUtt2H3wP3_Hh3C_tsFZq2KaR7Bh8sew9aWOMngCZvjR4YdMsby4MGNGNQxYGXhpn49y1PpslJ-NEhSFU1ZkrN3pzQ7Z51aPM5WnrNsfeoxut9mkQH9kjj_iRDyMc0pDYBN6_JhSFdun8PVGNvkMNvMiN8-BoVUUpkKEmie-jz5jEiZZ6kgTkQXOQ2nB24YqYl3XaqeWIeO4jBnwZIxox0RDMdKQBQdL6ElVo-QfcPtEYHGVYbsUbXGLKiK5QgSuBW9KCBJuuJ5WdY4GYk1lwtYgd9cgUSjpteG9NSJe4oUWdoRGZ4TzG_KMa6k5i1e0acHO5eGI444IxAK2HKWFKU4wN8WCQCg3XLrhNSChdAVa2YjjdsVNK-RcGVJBPwteN-y1Wv2qL_ri-l3swxbyVtw_HvR24C5O4lW8_y5szqcL8xLu6Iv5aDbdK0UHg-83zWN_AFZDqBo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tg02%2C+a+novel+oral+multi-kinase+inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+potent+anti-leukemic+properties&rft.jtitle=Leukemia&rft.au=Goh%2C+K.C&rft.au=Novotny-Diermayr%2C+V&rft.au=Hart%2C+S&rft.au=Ong%2C+L.C&rft.date=2012-02-01&rft.pub=Nature+Publishing+Group&rft.issn=0887-6924&rft.volume=26&rft.issue=2&rft.spage=236&rft_id=info:doi/10.1038%2Fleu.2011.218&rft.externalDocID=A280717751 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0887-6924&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0887-6924&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0887-6924&client=summon |